BioSpace News Archive

Pulse Biosciences, Inc. announced today that the Compensation Committee of the Company’s Board of Directors granted non-qualified stock options covering an aggregate of 17,000 shares of Pulse Biosciences common stock to two new non-executive employees under the Pulse Biosciences 2017 Inducement Equity Incentive Plan on November 15, 2018.

David Taylor who has revolutionised the science of high field preclinical scanning across the globe has been shortlisted for the HealthTech Founder of the Year award in the inaugural BMW i UK Tech Founder Awards.

NapaJen Pharma Co., Ltd., a biotherapeutics company leveraging its proprietary immune cell-targeted oligonucleotide delivery technology to develop novel immunotherapeutic agents, today announced dosing of the first patient in a Phase 1 first-in-human clinical trial of NJA-730 in healthy volunteers.

The Guardian Life Insurance Company of America (Guardian®), a leading national provider of life and disability insurance, employee benefits, and dental insurance, today announced its Board of Directors approved a $978 million dividend allocation to its individual life policyholders in 2019.

The Knowledge Economy Global Buyers Report analyzes the findings of Equiteq’s fifth comprehensive independent survey of global strategic buyers and private equity investors acquiring businesses across the knowledge economy.

The growth of the healthcare industry is expected to play a vital role in shaping the future prospects of the prefilled formalin vials market

Strategic prime vendor relationship with Medline saves system $8M+ to date by creating best-in-class distribution at Kentucky-based healthcare system

PerkinElmer, Inc. today announced that the Company will present at the 2018 Evercore ISI HealthCONx Conference on Thursday, November 29, at 10:15 a.m. ET at the Boston Harbor Hotel.

Oragenics, Inc. today announced it has received clearance to enroll patients residing in Germany from the Paul Erlich Institute and patients residing in the United Kingdom from the Medicines and Healthcare products Regulatory Agency (MHRA), into its Phase 2 clinical trial of AG013, a live biotherapeutic product for the potential prevention and treatment of OM.

Intersect ENT, Inc. today announced publication of a pooled analysis in the International Forum of Allergy & Rhinology, the official journal of the American Rhinologic Society, of the company’s PROPEL® Contour and PROPEL® Mini steroid releasing sinus implants showing improved outcomes of frontal sinus surgery.